| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/21/2009 | US20090131335 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131334 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131333 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131332 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131329 Treatment for allograft rejection |
| 05/21/2009 | US20090131326 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131325 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131324 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131323 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131322 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131320 Peptides modulating the activity of the engrailed transcription factor |
| 05/21/2009 | US20090131312 Non-natural chemokine receptor ligands and methods of use thereof |
| 05/21/2009 | US20090131308 Splice Variants of ErbB Ligands, Compositions and Uses Thereof |
| 05/21/2009 | US20090131303 Methods and compositions for treating dry eye |
| 05/21/2009 | US20090131302 Transient receptor potential vanilloid 1 and uses thereof |
| 05/21/2009 | US20090130715 Antibodies to CD40 |
| 05/21/2009 | US20090130692 Use of microproteins as tryptase |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130236 using a Sasa plant extract for treating herpes virus, influenza virus, corona virus infections |
| 05/21/2009 | US20090130232 Composition and method for treatment of oral inflammation an ulceration |
| 05/21/2009 | US20090130229 Antitumor uses of compound |
| 05/21/2009 | US20090130228 Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs |
| 05/21/2009 | US20090130225 Macrolides derivatives as antibacterial agents |
| 05/21/2009 | US20090130219 Composition for Improving Lipid Metabolism |
| 05/21/2009 | US20090130218 Association of Oleaginous Substance With a Mixture of at Least Two Cyclodextrins |
| 05/21/2009 | US20090130216 Multimodal particulate formulations |
| 05/21/2009 | US20090130215 Granular preparation containing biguanide compound |
| 05/21/2009 | US20090130214 Gemcitabine derivatives nanoparticles |
| 05/21/2009 | US20090130212 Composition and improved method for preparation of small particles |
| 05/21/2009 | US20090130210 Pharmaceutical compositions of sirolimus |
| 05/21/2009 | US20090130209 Novel Pyridazinone Derivatives |
| 05/21/2009 | US20090130206 Controlled Release Compositions of an Antidepressant Agent |
| 05/21/2009 | US20090130205 Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride |
| 05/21/2009 | US20090130204 Dosage Form Comprising Therapeutic Formulation |
| 05/21/2009 | US20090130202 Pharmaceutical Compositions |
| 05/21/2009 | US20090130201 polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| 05/21/2009 | US20090130200 Granules for controlled release of tamsulosin |
| 05/21/2009 | US20090130197 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt |
| 05/21/2009 | US20090130195 Prostate carcinogenesis predictor |
| 05/21/2009 | US20090130194 Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously |
| 05/21/2009 | US20090130193 Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally |
| 05/21/2009 | US20090130192 Class iii slrp agonists for the reduction of blood vessel formation |
| 05/21/2009 | US20090130190 Transdermal System for the Delivery of Sufentanil and Its Analogs |
| 05/21/2009 | US20090130189 Means for transdermal administration of nicotine |
| 05/21/2009 | US20090130184 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| 05/21/2009 | US20090130183 Bilayer Composition for the Sustained Release of Acetaminophen and Tramadol |
| 05/21/2009 | US20090130182 Topical compositions for treating pain |
| 05/21/2009 | US20090130180 Preparation for External Use |
| 05/21/2009 | US20090130178 Formulation for decreasing tobacco, alcohol, drug or food consumption |
| 05/21/2009 | US20090130177 Dental implant and production method for said implant |
| 05/21/2009 | US20090130176 Intraocular lens with drug delivery system attached thereto |
| 05/21/2009 | US20090130174 Poly (ester urethane) urea foams with enhanced mechanical and biological properties |
| 05/21/2009 | US20090130171 High concentration gentian violet containing medical devices and methods of making same |
| 05/21/2009 | US20090130170 Agent eluting bioimplantable devices and polymer systems for their preparation |
| 05/21/2009 | US20090130165 MIF Inhibitors |
| 05/21/2009 | US20090130163 Drugs With Improved Hydrophobicity For Incorporation in Medical Devices |
| 05/21/2009 | US20090130128 Antiinfective Proanthocyanidin Compounds and Methods of Use Thereof |
| 05/21/2009 | US20090130127 Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration |
| 05/21/2009 | US20090130123 Antibodies to west nile virus polypeptides |
| 05/21/2009 | US20090130117 Substituted Tetrazole Compounds and Uses Thereof |
| 05/21/2009 | US20090130116 Use of CEACAM8-Specific Substances for Treating Autoimmune Diseases and a Method for Screening Substances Which Induce Apoptosis |
| 05/21/2009 | US20090130113 Compositions and methods for use for antibodies against sclerostin |
| 05/21/2009 | US20090130112 Spatial for altering cell proliferation |
| 05/21/2009 | US20090130110 High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies |
| 05/21/2009 | US20090130109 DCL-1 and uses thereof |
| 05/21/2009 | US20090130108 N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy |
| 05/21/2009 | US20090130107 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 05/21/2009 | US20090130097 Quinazolinone Compounds and Methods of Use Thereof |
| 05/21/2009 | US20090130095 Composition comprising tumor necrosis factor (CD40) specific immunoglobulin for treatment and prevention of autoimmune diseases |
| 05/21/2009 | US20090130091 Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
| 05/21/2009 | US20090130090 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists |
| 05/21/2009 | US20090130083 Therapeutic Agents Targeting the NCCA-ATP Channel and Methods of Use Thereof |
| 05/21/2009 | US20090130080 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase |
| 05/21/2009 | US20090130078 Treatment for Cardiovascular Disease |
| 05/21/2009 | US20090130077 Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| 05/21/2009 | US20090130076 Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| 05/21/2009 | US20090130075 Energy generating composition |
| 05/21/2009 | US20090130069 Thymidine Kinase |
| 05/21/2009 | US20090130062 Novel Application of Heparin-Binding Epidermal Growth Factor-Like Growth Factor for Medical Purposes |
| 05/21/2009 | US20090130060 Modified Vitamin K Dependent Polypeptides |
| 05/21/2009 | US20090130057 Compounds for the Treatment of Hepatitis C |
| 05/21/2009 | US20090130056 Compounds for the Treatment of Hepatitis C |
| 05/21/2009 | US20090130055 Use of a Cytokine From the Interleukin-6 Family In the Preparation of a Composition For Combined Administration With Interferon-Alpha |
| 05/21/2009 | US20090130052 Biocide, in particular an agent with fungicidal activity |
| 05/21/2009 | US20090130051 Flavonoid Compounds and Uses Thereof |
| 05/21/2009 | US20090130049 Self-Sterilizing Products |
| 05/21/2009 | US20090130048 Topical Composition for Treating Pain |
| 05/21/2009 | US20090130035 Stabilized preparations comprising phenolic compounds and benzophenones |
| 05/21/2009 | US20090130027 Compositions and methods for treating purpura |
| 05/21/2009 | US20090130017 Targeted short-lived drug delivery |
| 05/21/2009 | CA2644179A1 Novel pharmaceutical composition comprising a disintegration matrix |
| 05/20/2009 | EP2060630A2 PCA3, PCA3 genes, and methods of use |
| 05/20/2009 | EP2060582A1 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| 05/20/2009 | EP2060575A1 Dihydrothienopyrimidines and their use in treating inflammatory diseases |
| 05/20/2009 | EP2060573A2 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine |
| 05/20/2009 | EP2060572A1 Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient |
| 05/20/2009 | EP2060570A2 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors |
| 05/20/2009 | EP2060569A1 Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulfonate hemihydrate and its use as a medicament |
| 05/20/2009 | EP2060565A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| 05/20/2009 | EP2060564A1 Non-peptidic promoters of apoptosis |